Loading...
3 results
Search Results
Now showing 1 - 3 of 3
- Memory awareness in patients with major depressive disorderPublication . Mendes, Tiago; Cardoso, Sandra; Guerreiro, Manuela; Marôco, João Paulo.; Silva, Dina; Alves, Luísa; Schmand, Ben; Couto, Frederico Simões Do; Figueira, Maria Luísa; De Mendonça, AlexandreSubjective Memory Complaints (SMC) along with cognitive deficits are frequently observed in patients with Major Depressive Disorder (MDD). The relationship between SMC and objective memory performance in patients with MDD was evaluated, in comparison with patients with Mild Cognitive Impairment due to Alzheimer's Disease (MCI-AD) and healthy controls (HC).
- Neuropsychological contribution to predict conversion to dementia in patients withmild cognitive impairment due Alzheimer’s diseasePublication . Silva, Dina Lúcia Gomes da; Cardoso, Sandra; Guerreiro, Manuela; Marôco, J. P.; Mendes, Tiago; Alves, Luísa; Nogueira, Joana Maia; Baldeiras, Ines; Santana, Isabel; Mendonça, Alexandre deDiagnosis of Alzheimer's disease (AD) confirmed by biomarkers allows the patient to make important life decisions. However, doubt about the fleetness of symptoms progression and future cognitive decline remains. Neuropsychological measures were extensively studied in prediction of time to conversion to dementia for mild cognitive impairment (MCI) patients in the absence of biomarker information. Similar neuropsychological measures might also be useful to predict the progression to dementia in patients with MCI due to AD.
- Neuropsychological profile of amyloid-positive versus amyloid-negative amnestic Mild Cognitive ImpairmentPublication . Alves, Luísa; Cardoso, Sandra; Silva, Dina; Mendes, Tiago; Maroco, J. P.; Nogueira, Joana; Lima, Marisa; Pereira, Miguel Tábuas; Baldeiras, Inês; Santana, Isabel; De Mendonça, Alexandre; Guerreiro, ManuelaPatients diagnosed with amnestic mild cognitive impairment (aMCI) are at high risk of progressing to dementia. It became possible, through the use of biomarkers, to diagnose those patients with aMCI who have Alzheimer's disease. However, it is presently unfeasible that all patients undergo biomarker testing. Since neuropsychological testing is required to make a formal diagnosis of aMCI, it would be interesting if it could be used to predict the amyloid status of patients with aMCI.